Fast, ready-to-use migraine pain relief1-3
Tosymra delivers migraine pain relief in as little as 10 minutes with just one spray for some patients (13% vs. 5% for placebo).*1-3
Efficacy of Tosymra is based on relative bioavailability to subcutaneous sumatriptan at a dose of 4 mg. In a clinical study, this dose of sumatriptan resulted in 57% of patients achieving pain relief at 2 hours vs. 21% for placebo.1
*Time to onset and degree of pain relief varies by patient.
Tosymra uses the science of Intravail®
Tosymra is the first and only triptan nasal spray to use the novel ingredient Intravail® to enhance drug absorption across the nasal mucosa.4
Tosymra for free†
The Access Pathways® Program is a best-in-class savings and support program. Access Pathways®, in partnership with Blink Pharmacy Plus, offers:
Eligible patients pay $0† per prescription, per month, renewable annually
Dedicated customer support to guide you and your patients through the process
†Restrictions apply. Platinum Pass® savings card or filling prescription through Blink Pharmacy Plus required. Maximum of eight single-dose nasal spray units per month. Medicare, Medicaid, and other federal and state healthcare program patients are not eligible.
Want more information?
Sign up today to learn more about Tosymra.
- Tosymra [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC: 2019.
- Mathew NT, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 1992;49(12):1271-1276.
- Wendt J, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics. 2006;28(4):517-526.
- Maggio ET. Intravail®: highly effective intranasal delivery of peptide and protein drugs. Expert Opinion Drug Delivery. 2006;3(4):529-539.